Abstract: Chronic hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in people coinfected with human immunodeficiency virus
Introduction
Hepatitis C virus (HCV) infection is prevalent among human immunodeficiency virus (HIV)-infected populations, with about 7 million people worldwide being coinfected [1] . The risk of liver-related mortality, predominantly attributed to HCV, has decreased since potent antiretroviral therapy (ART) became available and among the non-AIDS causes of death malignancies are nowadays the leading cause of death. The introduction of ART and the greater understanding of the life cycle of HCV and its interactions with the host have resulted in a reduction of hepatic decompensation and mortality in HIV/HCV coinfected subjects. However, liver-related mortality remains still higher among coinfected individuals compared with those with only HIV or HCV monoinfection [2] .
Interestingly, natural history studies have shown that HIV coinfection promotes accelerated HCV-related hepatic fibrosis progression, even with HIV replication under full control by ART [3] .
Although complex and multifactorial, the pathogenesis of accelerated hepatic fibrosis among HIV/HCV coinfected individuals is beginning to come to light [4] . HIV alters the natural history of HCV-related liver disease through mechanisms that are independent of its effects on T cell-mediated immunity [5] . The most relevant mechanisms involved include direct viral effects, immune/cytokine dys-regulation, altered levels of matrix metalloproteinases and fibrosis biomarkers, increased oxidative stress and hepatocyte apoptosis, HIV-associated gut depletion of CD4 cells, and microbial translocation. HIV also generates a metabolic pathway that leads to liver toxicity and processes such as steatosis and insulin resistance, which may aggravate liver disease. Finally, the potential role in liver injury of heavy alcohol consumption, as well drug use, should be taken into consideration [3, 6] .
In this review, we discuss the evidence and potential molecular mechanisms involved in the accelerated liver fibrosis seen in patients coinfected with HIV and HCV.
Pathophysiology of Liver Fibrosis in Chronic Hepatitis C Virus (HCV) Infection

Background Issues
Liver fibrosis is a reversible and dynamic response to hepatic injury. It can be caused by toxic, metabolic, or viral insult, and occurs when there is an imbalance in extracellular matrix (ECM) protein turnover, i.e., enhanced synthesis and reduced degradation. If, as in chronic HCV infection, the injury is prolonged, inflammation persists and accumulation of ECM proteins exceeds their degradation [7] , directly stimulating fibrogenesis [8] and leading to a progressive substitution of liver parenchyma by scar tissue. This in turn causes nodules of regenerating hepatocytes to develop, a feature that defines the progression of fibrosis to cirrhosis [9] .
Although recent studies have demonstrated that various types of liver cells are involved in hepatic fibrogenesis, the driving force behind this process is the hepatic stellate cells (HSCs), the primary cell sources of ECM [10] [11] [12] [13] . HSCs are generally quiescent in the hepatic perisinusoidal space [14] , but become active in response to chemical stimuli produced by hepatocytes or Kupffer cells following cell injury; these stimuli include reactive oxygen species (ROS), lipid peroxides, growth factors and inflammatory cytokines [10] . The most influential growth factors involved in HSC activation and collagen synthesis are transforming growth factor-β1 (TGF-β1) [15, 16] and platelet-derived growth factor (PDGF), which are secreted by hepatocytes and platelets, respectively, during liver injury and inflammation [7, 17, 18] . Levels of both TGF-β1 and all PDGF isoforms are upregulated during HSC activation, correlating with the development of liver fibrosis and hepatocellular carcinoma (HCC) [19] [20] [21] [22] [23] [24] [25] [26] . Once activated, HSCs convert into highly proliferative, myofibroblast-like cells, which produce inflammatory and fibrogenic mediators [7, 18] . Myogenic HSCs can differentiate to myofibroblasts, which possess pro-fibrogenic potential; in fact, myofibroblasts actively secrete ECM, including α-smooth-muscle actin (α-SMA) and fibrillar collagens (collagens I and III) [27] . HSCs also produce tissue inhibitors of metalloproteinases (TIMPs), which may reduce ECM degradation through suppression of the matrix metalloproteinase (MMP) activity [28] .
Interplay between HCV and Liver Inflammation and Fibrosis
Chronic HCV is characterized by progressive damage to liver tissue that leads to progressive fibrosis, potentially resulting in cirrhosis, liver failure and HCC [29] . Chronic inflammation is a major contributor to such diseases, and is the basis of HCV-mediated liver damage ( Figure 1 ) [30] . Immunophenotyping of lymphocytes that infiltrate the liver during HCV infection show that they include natural killer (NK), natural killer T (NKT), regulatory T cells, monocytes/macrophages, dendritic cells (DC) and, predominantly, CD4 + and CD8 + cells, suggesting that the host immune system is involved in the pathogenesis of the resulting liver disease [31] [32] [33] [34] [35] .
The T-cell response is essential for identification and clearance of HCV, either by cytolysis of virus-infected cells or non-cytolytic clearance via cytokine or chemokine-mediated effects. A greater T-cell response (both virus-specific CD4 + and CD8 + cells) during acute, rather than chronic, HCV has been reported [36] [37] [38] , and a strong influence of chemokine-chemokine receptor interactions on the recruitment of T cells to sites of inflammation in the liver during chronic HCV infection has been reported [39] . Some genetic studies have found that polymorphisms in the HLA class I and class II molecules on chromosome 6, which are linked to CD8 and CD4 responses, respectively, are associated with spontaneous HCV clearance, thereby confirming the importance of T cells in the elimination of HCV infection [40] [41] [42] [43] .
Expression of intrahepatic chemokine ligands and their receptors has been associated with severe HCV-induced liver inflammation [44] [45] [46] . The release of inflammatory cytokines and chemokines is induced by the crosstalk between HSCs and HCV-infected hepatocytes [47] . It is likely that inflammatory cell activation is triggered by HCV core and NS3 proteins inducing interleukin (IL)-1 receptor-associated kinase (IRAK) activity through toll-like receptor 2 (TLR)-2 [48] . HCV-associated IRAK activation may also contribute to the induction of cytokines and chemokines by HSCs.
The expression of C-C chemokine receptor type 5 (CCR5) on activated T cells relies upon their recruitment to the liver [49] . Indeed, intrahepatic expression of the ligands for CCR5 (RANTES, MIP-1β, and MIP-1α), which have been linked to a high grade of liver inflammation [50] , is elevated in HCV-infected patients. Chronic HCV infection is also known to be associated with increased levels of tumor necrosis factor (TNF)-α in the liver and serum of patients [51, 52] . Considering that TNF-α elevation may interfere with insulin signaling [53] , this cytokine could be the key molecular link between inflammation, steatosis, and fibrosis in chronic HCV infection. At present, however, we can state that HCV infection induces the generation of inflammatory cytokines and chemokines, potentially leading to the recruitment of inflammatory cells such as cytotoxic T lymphocytes (CTL), neutrophils, monocytes, DCs, and NK cells to the liver, causing liver cell injury and chronic hepatitis [33] [34] [35] . HCV infection also promotes the activation of macrophages, in particular Kupffer cells, which release ROS and large amounts of proinflammatory and fibrogenic mediators [54] [55] [56] [57] , such as TGF-β1. Several studies have demonstrated increased TGF-β1 secretion from HCV-infected cells, feasibly driving HSC activation and hepatic fibrogenesis [58] [59] [60] [61] [62] . In addition, both Kupffer cells and activated human HSCs express TLR4-the main target of lipopolysaccharide (LPS), which is released in great amounts during microbial translocation associated with both HCV and HIV infections.
The inflammation and fibrosis of the liver seen during chronic HCV infection is also closely related to the increased apoptosis of damaged hepatocytes. Indeed, a growing body of evidence from both experimental and clinical studies suggests that hepatocyte apoptosis may contribute to liver fibrogenesis by promoting the activation of Kupffer cells and stimulating the fibrogenic action of liver myofibroblasts [63] . Following the uptake of apoptotic bodies [64] , Kupffer cells express death ligands such as TNF-α, TRAIL and FasL [65] [66] [67] [68] [69] [70] . All these death ligands can induce apoptosis in hepatocytes via death-receptor-induced signaling cascades, and thereby aggravate liver injury [71] . In addition, activated myofibroblasts are able to engulf apoptotic bodies and subsequently produce profibrogenic factors such as TGFβ-1 [65] .
Accelerated Liver Fibrosis in Human Immunodeficiency Virus (HIV)/HCV Coinfection
Multiple factors are implicated in the mechanisms of liver fibrosis progression in patients with HIV/HCV coinfection (Table 1) .
Direct Effects of HIV
Several epidemiological and clinical findings indicate a direct role of HIV in inducing liver fibrinogenesis [72, 73] even in patients with no concomitant viral hepatitis coinfection. In a large North American study in four groups of women (HCV monoinfected, HIV monoinfected, HIV/HCV coinfected and HIV-seronegative/HCV-seronegative women), HIV-RNA plasma levels were associated with increased FIB-4 score in the absence of HBV, HCV, ART or alcohol use [74] . Using transient liver elastography, liver damage has been frequently detected in HIV-monoinfected patients [75] [76] [77] and correlated with high plasma HIV-RNA levels [78] . In addition, the benefit that ART has on the progression of liver damage (both on biopsies and on clinical events) is well documented [79] . The control of HIV replication by ART dramatically reduces risk of hepatic decompensation and risk of dying from liver disease. In biopsy studies this has been correlated also with less inflammation in the histologies obtained.
Therefore, the increased risk of liver disease progression in HIV-monoinfected patients emphasizes the impact of a direct role of HIV in the induction of liver fibrinogenesis ( Figure 2 ) [72, 73] . Indeed, hepatocytes (and other resident liver cells) are known to express key HIV co-receptors, including CCR5 and C-X-C chemokine receptor type 4 (CXCR4) [80] [81] [82] [83] and HIV itself has direct cytopathic effect on hepatocytes [73] . A productive HIV infection was demonstrated in hepatocytes, through identification of hepatotropic variants of HIV in autopsied liver tissues [84] and, more recently, in HSC by detection of p24 antigen and HIV-RNA [85] . Both HIV and its envelope protein gp 120 have been shown to induce cell signaling in the liver through interactions with the CCR5 and CXCR4 expressed on the surface of hepatocytes, HSCs and other immune cells [60, [85] [86] [87] [88] [89] , and in vitro models have shown that both inactivated HIV and gp 120 enhance HCV viral replication and TGF-β1 expression [57, 85, 88, 90] . This effect of HIV and gp 120 on HCV replication is blocked by antibodies for CCR5 or CXCR4, indicating that CXCR4 or CCR5 co-receptor engagement by HIV is essential for stimulation of HCV replication [57] . The effect of HIV on HCV replication is also blocked by a neutralizing antibody to TGF-β1, one more indicator that HIV itself could directly contribute to hepatic fibrosis and increased HCV replication in a TGF-β1-dependent manner [57] .
Transcripts for the chemokine receptors CCR5 and CXCR4 (which bind gp 120) are detectable in human HSCs [89, 91, 92] . Upon exposure to CCR5-tropic recombinant gp 120, a significant increase in HSC chemotaxis has been observed, as has increased expression of the proinflammatory chemokine monocyte chemoattractant protein-1 (MCP-1), interleukin-6, and tissue inhibitor of metalloproteinase-1 (TIMP-1) [88] . It has therefore been speculated that gp 120 may induce HSC accumulation through direct chemotaxis and secretion of MCP-1 by HSCs themselves, and by activated macrophages, thereby leading to increased liver inflammation and fibrogenesis [85, [93] [94] [95] . Recent experiments using in vitro models have also suggested that concurrent exposure of hepatocytes to HCV-E2 protein and HIV gp 120 can directly promote hepatocyte apoptosis through upregulation of FasL expression via the STAT1-dependent pathway. This occurs in a CXCR4-independent manner [81, 96] and results in higher viral loads through induction of TGF-1β, a cytokine that dampens the immune response and promotes fibrosis and transformation towards HCC [57, 97] .
The fibrogenic response by HSCs seems to be mediated by the activation of an autocrine loop involving the chemokine receptor CCR5 [89, 98] . Recent experiments in animal models have detected significant reductions in the levels of IL-6, MMP-9, and TGF-β1 when animals were treated with CCR5 antagonists, indicating that these molecules are key regulatory factors of fibrosis through CCR5-signaling interference [99] [100] [101] . The potential anti-fibrotic effects of maraviroc (MVC), a CCR5-specific HIV-entry inhibitor currently in use in antiretroviral therapy, are currently being investigated in HIV/HCV coinfected patients [102, 103] . There is some preliminary evidence that maraviroc, given to such patients to reduce their HIV load, also leads to a reduction in liver stiffness [104] . In addition, treatment with MVC, a CCR5 inhibitor, has also been shown to significantly reduce fibrosis and tumour load in a mouse model of HCC [99] .
NALP (NACHT, LRR and PYD-containing protein) 3 inflammasome is a critical step in the proinflammatory signal generation pathway during liver injury, and a possible direct link between the inflammasome pathway in monocytes and HSC and HIV proteins is currently under evaluation. Another likely contributory mechanism to liver fibrosis is the production of reactive oxygen species in HSCs, known to be triggered by both X4-tropic and R5-tropic HIV [87] . Both HIV and HCV act upon hepatocytes and HSCs to stimulate the generation of ROS, which in turn induces p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinases (ERKs), followed by activated nuclear factor kappa (NF-κB). This supports the pro-fibrogenic TGF-β1 genes, which encode collagen and TIMP-1, as well as down-regulating MMP-3 synthesis. Hence both HCV and HIV are directly involved in liver damage by triggering apoptosis and down-regulating antioxidant protective mediators.
HIV-Associated Dysregulation of the Immune Response and Cytokine Network
The quantitative and qualitative impairment of T-cell responses associated with HIV infection may have a negative impact on HCV disease progression. Considering both the critical role of the adaptive immune system in the clearance of HCV and the detrimental effect of HIV infection on T-cells, it is not surprising that HCV persistence in HIV/HCV coinfection is more common than in patients infected with HCV alone. Several lines of evidence indicate that HIV-induced CD4 depletion is independently associated with the severity of liver fibrosis in chronic HCV infection. In particular, a recent study has demonstrated that both HIV-induced loss of CD4 + T cells and dysregulated CD4 + T cell function lead to a reduction in the anti-fibrotic activity of NK cells, which plausibly results in the accelerated progression of liver fibrosis seen in patients with HIV/HCV co-infection [105] . In addition, a marked intrahepatic CD4 T-cell depletion, associated to an increase in apoptotic lymphocytes in the liver lobule, has been demonstrated in HIV/HCV coinfected patients.
The altered balance between CD4 and CD8 response in HIV infection may be ascribable to a profound dysregulation of the peripheral and intrahepatic cytokine networks, which plays an important role in the accelerated evolution of liver fibrosis (Figure 2 ). A potential mechanism by which reduced CD4 cell counts promote hepatic fibrosis is a reduction in the secretion of T-helper (Th) 1 cytokine IFN-γ, a well-known anti-fibrotic cytokine. On the other hand, the increased Th2 response seen in HIV infection is associated with secretion of Th2 cytokines (IL-4, IL-5, IL-10, and IL-13), which are known to play a pro-fibrotic role in liver fibrosis [106] . As mentioned above, an important mediator of liver fibrogenesis is the cytokine TGF-β1, which favors activation of hepatic HSC and stimulates ECM production [107] . Significant increases in TGF-β1 expression have been reported in the liver and serum of patients with HIV/HCV coinfection; HIV enhances HCV-related increases in TGF-β1 from hepatocytes, thereby enhancing fibrogenesis.
Another cytokine associated with liver inflammation and immunoregulatory pathways in the liver parenchyma is IP-10 (CXCL10). IP-10 is a CXC chemokine that binds to the CXCR3 immune system receptor present on a number of cells, including monocytes, NK cells and T cells. Various studies have identified elevated IP-10 levels as a negative prognostic indicator for both HCV infection and HIV infection, and it has also been proposed as a negative predictor of response to antiviral therapy in HCV mono-infected and HIV/HCV co-infected patients [108, 109] . A high rate of inflammation, and subsequent activation of the endogenous IFN system, as well as significant levels of oxidative damage [110] , have been proposed as mechanisms behind IP-10 elevation. It is believed that elevated IP-10 could recruit T cells from the periphery and within the liver, mediating the damage seen in advanced fibrosis [19] . The mechanism by which elevated levels of IP-10 may affect HCV infection in individuals with HIV and HCV coinfection is, however, unknown. Nevertheless, it has recently been suggested that the regulatory protein HIV tat is able to induce IP-10 expression and subsequently increases the replication of HCV and HCV/HIV in coinfected individuals [111] .
IL-1 dysregulation may also play a role in maintaining the HSCs in the proliferative state responsible for hepatic fibrogenesis in HCV/HIV coinfection, as shown in a rat model. IL-1β is a central component of the cytokine milieu that accompanies both acute and chronic inflammation and viral disease [112, 113] . As a pleiotropic inflammatory factor, IL-1β has also been implicated in promoting tissue pathology and inducing the production of pro-fibrogenic mediators [114] [115] [116] [117] . Inflammasome and IL-1β have also been recognized as potentially key factors in an innate mechanism, alternative to type I interferon, able to recognize nucleic acids (DNA or RNA) and cytoplasmatic viral particles and consequently induce a pro-inflammatory response [118] . Indeed, several viruses are able to activate caspase-1 and induce IL-1β production through inflammasome signaling, highlighting the potential role of inflammasomes in the immune response to viruses [119] . In fact, a recent study has shown that IL-1β production and hepatic inflammation in HCV infection, induced by phagocytic uptake of the virus, are linked and driven through endosomal TLR7 and NLRP3 inflammasome signaling in liver macrophages/Kupffer cells [30] . Moreover, HCV products induce intracellular reactive oxygen species and ion flux, both of which trigger the NLRP3 inflammasome during virus infection. Finally, the HCV p7 protein is a transmembrane cation channel that also drives ion flux, and is thereby also a potential mediator of NLRP3 inflammasome activation during HCV infection [120] . In fact, high levels of IL-1β have been observed in patients from the early stages of HIV infection, suggesting a role of NLRP3 inflammasome in driving the inflammatory response and subsequent liver fibrosis [121] .
Finally, recent studies have highlighted the impact of IL-6 levels on liver fibrosis in HIV and HCV coinfected patients. IL-6 is secreted by T cells and macrophages in response to microbial products and other stimuli and it represents a marker of systemic immune activation and liver inflammation [122] . It has been shown that high circulating levels of IL-6 are associated with portal hypertension and decompensated liver cirrhosis in both HIV-infected and -uninfected patients [123] . In a large study on biomarkers of inflammation, it has been reported that higher concentrations of IL-6 in HIV-infected individuals coinfected with HBV and/or HCV were associated with death within 4 years of ART initiation. Moreover, high levels of IL-6 are predictive of failure to antiviral therapy in HIV/HCV coinfected patients [124] .
Role of Immune Activation and Microbial Translocation
It has long been recognized that HIV infection is characterized not only by the development of profound immunodeficiency, but also by a marked and persistent cellular immune activation. The central role of immune activation in the pathogenesis and progression of HIV disease has been highlighted by both animal and human studies. It has been demonstrated that the major driving force behind chronic immune activation is the translocation of microbial products from the damaged gastrointestinal (GI) tract to the portal and systemic circulation. During HIV infection, the massive depletion of CD4 T cells in the intestine leads to an alteration of the immune component of the surface of the GI mucosa that can induce greater translocation of LPS [125] . Increased levels of circulating LPS have been shown during HIV infection, suggesting greater immune activation and a consequent progression of the disease, alongside CD4 + T cell depletion [126] . LPS also raises levels of macrophage activation marker sCD14, also considered an indicator of inflammation [127] . Interestingly, high plasma levels of sCD14 have been correlated to an increased risk of mortality in HIV-infected patients [128] , while LPS has been proposed as a useful biomarker of progression of the disease, regardless of CD4 + T cell count or viral load [129] . sCD14 and LPS are undoubtedly important indicators of liver disease progression in HIV/HCV-co-infected persons [129] . LPS has been shown to accelerate liver fibrosis through engagement of TLR-4 on hepatocytes and HSC following membrane binding via LPS-binding protein (LBP) and CD14. These events lead to simultaneous TGF-β1 stimulation through an NF-κB-dependent pathway and Kupffer cell activation, which, in turn, induces the generation of superoxide and the release of pro-inflammatory and pro-fibrogenic cytokines such as TNF-α, IL-1, IL-6, and IL-12, all of which induce liver damage [130] .
Microbial translocation in the host with severe liver fibrosis leads to a reduced clearance of bacterial products and increased immune activation (Figure 2 ) [131] . Consistent with these findings, the high degree of microbial translocation and immune activation observed in patients with both HIV and HCV infection has a great impact on the progression of liver fibrosis. Therapeutic strategies designed to down-regulate the state of immune activation and to counteract microbial translocation may therefore be potentially useful for keeping liver fibrosis in HIV/HCV co-infection under control.
Dysregulation of Matrix Metalloproteinases and Role of Fibrosis Biomarkers
To reiterate, liver fibrosis is characterized by a pathological accumulation of the extracellular matrix, reflecting the imbalance between enhanced matrix synthesis and reduced breakdown of connective tissue proteins. Extracellular degradation of matrix proteins is regulated by the matrix metalloproteinases (MMPs), a large family of zinc-dependent endopeptidases. Different levels of MMP regulation ensure the constant remodeling of the ECM, including regulation at the gene expression level, cleavage of the pro-enzyme to an active form, and specific inhibition of activated forms by TIMPs [132] . It is feasible that excessive or inappropriate expression of MMPs and/or a reduction in TIMP production could contribute to different pathological conditions, not only infectious diseases and liver fibrosis, including inflammation, wounds, and invasion of cancer cells [11] [12] [13] . MMP-1/-13 levels do not change in human and animal models of chronic liver disease, but there is a progressive increase in TIMP-1 and TIMP-2 as the fibrosis advances [133] . There is also evidence that activation of HSC in tissue culture models and during fibrotic liver injury in vivo is associated with the expression of potent matrix-degrading MMP inhibitors, including TIMP-1 and TIMP-2. With regard to chronic hepatitis C, an association between hepatic fibroproliferation and alterations in circulating and hepatic MMP and TIMP expression has been reported (Figures 1 and 2 ). HIV/HCV coinfected patients also exhibit a striking increase in circulating TIMP-1 levels, which is more evident in patients with more advanced CD4 depletion. On the other hand, there is no increase in the plasma concentrations of MMP-9, suggesting an imbalance between circulating TIMP-1 and MMP-9 during HIV infection [134] . It is possible that this altered balance may play a potential role in exacerbating the progression of liver fibrosis in HIV patients coinfected with HCV [133] .
Cytokines such as TNF-α, TGF-β, IL-1, and IL-6 are involved in the expression pattern of both MMPs and TIMPs. It is conceivable that the cytokine dysregulation documented in HIV contributes to the activation of HSC [135] and the upregulation of TIMPs, which, in turn, promote the progression of hepatic fibrosis by inhibiting matrix degradation. Finally, translocated LPS, which directly correlate with several independent aspects of innate and adaptive immune activation, might also be involved in the regulation of MMP and TIMP expression. Due to its potential role in HIV-associated immunopathology, MMP enzyme activity might constitute a novel therapeutic target in HIV infection [136] .
As for fibrosis markers, some studies on patients infected with HCV report that hyaluronic acid (HA) is an accurate indicator of fibrosis and predictor of individual hepatic complications. HA is a biomarker component of the extracellular matrix that is eliminated from the bloodstream by the liver sinusoids [137] . High CD4 counts in patients with HCV/HIV coinfection have been associated with a reduced risk of substantial increases in HA levels and hepatic fibrosis. Indeed, patients with low and stable plasma HA levels have a very low risk of liver disease progression. HA is also a strong predictor of later development of hepatic encephalopathy or liver-related death in HIV-1/HCV coinfection, and a higher annual increase of HA has been reported in patients experiencing liver-related events during follow-up, as compared with those who did not. Hence HA plasma detection, alone or in combination with other non-invasive methods, may be a useful means of monitoring the progression of liver disease and predicting the risk of hepatic complications in HIV/HCV coinfected patients [138] .
Role of Metabolic Alterations
Metabolic alterations are common during HIV/HCV coinfection, and play an important role in the genesis of hepatic steatosis, which is closely related to liver fibrosis progression (Figure 3 ) [139] [140] [141] [142] . These alterations, including dyslipidaemia and insulin resistance (IR), are due to a direct role of the virus, as well as chronic inflammation, deterioration of immunological status, and toxic exposure to antiretroviral therapy. Both HIV itself and the antiretrovirals given to mitigate its effects promote the development of IR and the abnormal deposition of fatty acids in hepatocytes through mitochondrial dysfunction. With regard to antiretroviral drugs and their risk for causing insulin resistance, there are evidence that protease inhibitors, such as indinavir [143] and lopinavir/ritonavir [144] , have effects on peripheral lipolysis through inhibition of glucose transporter type 4 (GLUT-4) activity. On the other hand, transcriptase inhibitors (NRTIs), such as zidovudine/lamivudine [145] may affect mitochondrial function which further contribuite to the induction of hepatic insulin resistance in HIV patients receiving ART [146] . Insulin resistance itself may play a key role in the pathogenesis of so-called virus-associated fatty liver disease (VAFLD), which in turn leads to liver steatosis and inflammation [147] [148] [149] [150] [151] . Furthermore, high levels of insulin and glucose stimulate HSC proliferation and increase the expression of one of the major factors involved in the progression of fibrosis-connective tissue growth factor (CTGF) [152] . Moreover, there is strong evidence for a central role of mitochondrial dysfunction in the pathophysiology of hepatic steatosis [153] . A recent study also showed that HIV infection has direct effects on mitochondria [154] -HIV and its polypeptides seem to undermine mtDNA and provoke other mtDNA-independent mitochondrial alterations [155] . Emerging evidence suggests that there is a link between immunological and metabolic perturbations. In particular, the increased production of proinflammatory cytokines and perturbance in adipokines (including adiponectin, leptin, resistin, and visfatin) detected in HIV/HCV coinfected patients [141, 156] may have an effect on insulin resistance, even promoting metabolic syndrome [139, 140] . Another recent study also found that lower levels of adiponectin are associated with advanced hepatic injury [156] . Adiponectin reduces body fat and enhances insulin sensitivity [157] , but also reduces inflammation by stimulating secretion of anti-inflammatory cytokines, such as IL-10, inhibiting the release of pro-inflammatory cytokines like IL-6 and TNF-α and blocking nuclear factor κB activation [157] .
As previously discussed, HIV/HCV coinfection and the consequent low levels of adiponectin may induce hepatic and systemic inflammation, which could lead to increased expression of resistin and leptin. Several studies have shown that resistin and leptin have a pro-fibrogenic and pro-inflammatory role [158] . Resistin causes expression of pro-inflammatory chemokines and IL-8, induces activation of transcription factor NF-κB, and has pro-inflammatory actions in HSCs [159] . Leptin mediates HSC activation and liver fibrosis through indirect effects on Kupffer cells partially mediated by TGF-β1 [160] . Unsurprisingly, therefore, low serum levels of resistin and leptin could contribute to controlling inflammation and reducing hepatic damage [155] .
Role of Alcohol and Drug Use
Most HIV and HCV coinfected individuals, at least in the developed world, are former or active intravenous injection drug users (IVDU) [3] . In addition to heroin, other substances, such as cannabis, amphetamine and cocaine, cause liver injury and fibrosis progression [161] . A study of 272 untreated patients with HCV hepatitis demonstrated that daily cannabis smoking is a risk factor for progression of liver fibrosis [162] . Amphetamines have an extensive hepatic metabolism and the generation of a toxic metabolite may be the cause of hepatic injury [163] . Cocaine can lead to a range of liver abnormalities and its metabolites are involved in oxidative stress and lipid peroxidation in hepatocytes [164, 165] .
On the other hand, among HIV/HCV coinfected drug users there is a high prevalence of heavy alcohol use [6, 166] which plays a potential role in liver disease progression. Indeed, it is known that alcohol is metabolized in the liver and promotes glutathione depletion and lipid peroxidation leading to mitochondrial damage [167, 168] and local lymphocyte recruitment [169] . Furthermore, acetaldehyde plays a central role in fibrogenesis by increasing the expression of collagen during HSC activation [170] . Alcohol use may also inhibit the anti-fibrotic action of NK cells [171] and it increases gut permeability and translocation of bacterial products such as LPS [172] which is also involved in fibrogenesis.
Conclusions
The pathophysiology of accelerated liver fibrosis in patients with HIV and HCV coinfection is a complex and multifactorial process involving viral factors, the immune system, and fibrinogenetic/ inflammatory mediators. Hence advances in the understanding of fibrosis pathophysiology and regulation are critical for the development of therapeutic strategies. As new information regarding fibrogenesis comes to light, the key challenge will be translating such advances into the development of anti-fibrotic therapies useful for patients with chronic liver disease, such as that seen in HIV/HCV coinfection.
